Claims
- 1. An isolated polypeptide comprising dentonin, wherein said polypeptide is characterized by a biological activity that induces a 25-hydroxyvitamin D3 1α-hydroxylase activity.
- 2. The isolated polypeptide of claim 1, wherein said dentonin is at least 50% identical to 15 contiguous amino acids of any one of SEQ ID NOS:1-18.
- 3. The isolated polypeptide of claim 1, wherein said dentonin comprises the sequence:
- 4. The isolated polypeptide of claim 1, wherein the polypeptide comprises at least 15 contiguous amino acids any one of SEQ ID NOS: 1-18.
- 5. The isolated polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.
- 6. The isolated polypeptide of claim 1, wherein the polypeptide is further characterized by a biological activity that does not significantly induce vitamin D 24-hydroxylase activity.
- 7. The isolated polypeptide of claim 1, wherein the polypeptide is further characterized by a biological activity that increases calcitriol amounts.
- 8. An isolated nucleic acid encoding the polypeptide of claim 1.
- 9. A method for increasing 25-hydroxyvitamin D3 1α-hydroxylase activity in a cell, said method comprising:
contacting said cell with an isolated polypeptide of claim 1;wherein 25-hydroxyvitamin D3 1α-hydroxylase activity is increased in said cell in comparison to a cell not contacted with the isolated polypeptide of claim 1.
- 10. The method of claim 9, wherein vitamin D 24-hydroxylase activity is not significantly induced in said cell.
- 11. The method of claim 9, wherein said cell is a cell of a mammalian host.
- 12. A formulation comprising:
a therapeutically effective amount of a polypeptide of claim 1.
- 13. The formulation of claim 12, further comprising a carrier.
- 14. The formulation of claim 13, wherein the carrier is a saline solution and the formulation is injectable.
- 15. A method for increasing levels of calcitriol in a subject, said method comprising:
administering to said subject a therapeutically effective amount of the formulation of claim 12;to increase said levels of calcitriol.
- 16. A method for treatment of a subject in need of said treatment, said method comprising:
administering to said subject a therapeutically effective amount of the formulation of claim 12;to treat said subject.
- 17. The method of claim 16, wherein said subject has a vitamin-D related condition.
- 18. The method of claim 17 wherein the condition is rickets, osteomalacia, osteoporosis, Paget's disease, osteopenia, osteosclerosis or renal osteodystrophy, psoriasis, medullary carcinoma, Alzheimer's disease, hyperparathyroidism, hypoparathyroidism, pseudoparathyroidism, secondary parathyroidism, diabetes, cirrhosis, obstructive jaundice or drug-induced metabolism, glucocorticoid antagonism, hypercalcemia, malabsorption syndrome, steatorrhea, chronic renal disease, hypophosphatemic vitamin D-resistant rickets, vitamin D-dependent rickets, rickets type I, rickets type II sarcoidosis, leukemia, prostate cancer, breast cancer, colon cancer, organ transplantation, bone fracture, undecalcified teath or an immunodisorder.
- 19. The method of claim 18 wherein the disease is osteoporosis, Paget's disease, osteomalacia, rickets, renal osteodystrophy, hyperparathyroidism, hypercalcemia, rickets type I, rickets type II and bone fracture.
- 20. A system for increasing target nucleic acid expression in a cell, said system comprising:
(a) isolated dentonin polypeptide; and (b) a 25-hydroxyvitamin D3 1α-hydroxylase promoter operably linked to said target nucleic acid, wherein said dentonin induces the activity of said 1α-hydroxylase promoter to increase the expression of said target nucleic acid.
- 21. A method of increasing the expression of a target nucleic acid in a cell, said method comprising:
operably linking a target nucleic acid to a 1α-hydroxylase promoter to form an expression cassette; transferring said expression cassette into a cell; and contacting the cell with the isolated polypeptide of claim 1, to increase expression of said target nucleic acid.
- 22. The method of claim 21 wherein the cell is a kidney cell.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 60/355,548 filed Feb. 8, 2002; the disclosures of which application is herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60355548 |
Feb 2002 |
US |